The reporter learned that Enerxin Capsule is a national second-class antiviral drug developed by Shijiazhuang No.4 Pharmaceutical Co., Ltd., and obtained the national new drug certificate and production approval in June 5438+ 10, 2004. Recently, the in vitro and in vivo experimental reports released by the State Key Laboratory of Virology show that Enerxin capsule has obvious inhibitory effect on the growth of influenza A virus (H 1N 1) in cells, and its blocking effect on the invasion of influenza A virus into cells is the same as that of Tamiflu, and its blocking effect on the invasion of influenza A virus into cells is stronger than that on virus biosynthesis, which can improve the growth of influenza A virus (H/kloc-0).
It is understood that in 2002-2003, Peking Union Medical College Hospital, China-Canada Friendship Hospital and PLA Air Force General Hospital conducted clinical trials on Enerxin Capsule, and completed 58 cases, 100 cases and 74 outpatient cases respectively. The results showed that Enerxin capsule can obviously shorten the course of disease and reduce the severity of symptoms when used in the early stage after the onset of influenza, and it is safe and well tolerated, so it is suitable for clinical use.
Professor Lin Jiangtao, director of the Department of Respiratory Medicine of the China-Japan Friendship Hospital of the Ministry of Health, vice chairman of the Respiratory Branch of the Chinese Medical Association, member of the National Expert Advisory Committee on Public Health Emergencies, and deputy head of the medical rescue team, believes that although the mechanisms of action of the two drugs are different, the therapeutic effects are basically the same, with less side effects. Enerxin can induce human body to produce interferon, enhance human body's antiviral ability, have a good effect on preventing influenza, have low cost, and be more economical and safer to popularize. Enerxin was successfully developed and achieved good market benefits, which was the result of years of independent innovation by Shijiazhuang No.4 Pharmaceutical Company. "During this year 1- 10, the sales revenue increased by 13.7% compared with the same period of last year, and the profit and tax increased by 18.9%. More than 80% of the contribution comes from the new drugs we have developed. " Qu Jiguang said.
The company invests about 30 million yuan in the research and development of new products every year, and more than a dozen new varieties come out every year, realizing the cascade development mode of producing and developing a number of new products. He has participated in the formulation of many national standards such as Packaging Standard for Large Infusion Containers and Sterilization Technology for Infusion by the National Pharmacopoeia Committee, and undertaken research tasks related to key research projects of the National Eleventh Five-Year Plan for Science and Technology. Innovate the market and create benefits. In addition to selling well in the domestic market, Shijiazhuang's four major pharmaceutical products are also exported to more than 40 countries and regions such as Bolivia, Benin, Sweden, Turkmenistan and Vietnam, and 30 kinds of products are registered in 1 1 countries such as Vietnam, Benin and Uzbekistan. This year, export delivery value has accumulated more than 60 million yuan.